haloperidol has been researched along with Idiopathic Parkinson Disease in 139 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dopamine-induced Gs hyperfunction characteristic of untreated patients with schizophrenia was not detected under antipsychotic treatment with either haloperidol or clozapine." | 7.71 | Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. ( Avissar, S; Roitman, G; Schreiber, G, 2001) |
| " It seemed sensible to investigate whether or not HP+ might be toxic towards dopaminergic neurons and perhaps associated with some of the residual moto-function side effects of haloperidol." | 5.29 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. ( Fang, J; Yu, PH; Zuo, D, 1995) |
| " In the Gilles-de-la-Tourette syndrome nicotine reduces the severity and frequency of the tics given in combination with haloperidol." | 4.79 | [Nicotine in neuropsychiatric movement disorders]. ( Erdmann, R, 1996) |
| "Dopamine-induced Gs hyperfunction characteristic of untreated patients with schizophrenia was not detected under antipsychotic treatment with either haloperidol or clozapine." | 3.71 | Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. ( Avissar, S; Roitman, G; Schreiber, G, 2001) |
| "In schizophrenia and Parkinson's disease, cortical and subcortical motor organization is influenced by primary disease conditions and neuroleptic treatment." | 2.71 | Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study. ( Deuticke, C; Hajak, G; Müller, JL; Putzhammer, A; Röder, CH; Winkler, J, 2003) |
| "However, the performances of Huntington's disease subjects appeared to be different when compared to the other two groups." | 2.69 | Kinematic analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects. ( Bonfiglioli, C; Castiello, U; De Berti, G; Nichelli, P; Nicoletti, R, 1998) |
| "and discussion: Chronic administration of 50, 100 and 200 mg/kg of DM extract improved the 14-s latency time induced by haloperidol to 54, 54 and 57 s respectively, whereas levodopa (30 mg/kg) produced 47 s in rotarod tests." | 1.91 | Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies. ( Adekunle, AO; Alananzeh, WA; Amali, MO; Ayipo, YO; Badeggi, UM; Lawal, BA; Mordi, MN, 2023) |
| "When lisuride NE was administered intranasally resulted in considerably higher dopamine concentrations (17." | 1.91 | Designing lisuride intranasal nanocarrier system for reduction of oxidative damage with enhanced dopamine level in brain for Parkinsonism. ( Gupta, SK; Kumar, S; Pahwa, R, 2023) |
| "The treatment of haloperidol-treated rats with quercetin was successful in reversing the haloperidol alterations." | 1.72 | Inhibition of drug induced Parkinsonism by chronic supplementation of quercetin in haloperidol-treated wistars. ( Arshad, M; Farhan, M; Rafi, H; Rafiq, H; Rehman, S; Shakeel, S, 2022) |
| "Subsequently, catalepsy tests were performed again." | 1.51 | Influence of aversive stimulation on haloperidol-induced catalepsy in rats. ( Barroca, NCB; Brandão, ML; Colombo, AC; da Silva, NT; de Oliveira, AR; Guarda, MD; Reimer, AE, 2019) |
| "Oxidative stress models, which had Parkinson's disease-like symptoms, were used to evaluate the antioxidant activity of nanoemulsion loaded with selegiline in vivo." | 1.48 | Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ( Ali, J; Baboota, S; Dang, S; Kumar, S; Nigam, K, 2018) |
| "Domperidone treatment in intact animals evoked a significant increase in normoxic tidal volume, while haloperidol potentiated tidal volume increase in response to hypoxia." | 1.43 | Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease. ( Andrzejewski, K; Budzińska, K; Kaczyńska, K; Zaremba, M, 2016) |
| " Pharmacokinetic results of CSNE(ROP) in Wistar rat brain and plasma showed a significantly high (p** < 0." | 1.42 | Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. ( Ahuja, A; Al Rohaimi, AH; Ali, J; Baboota, S; Hassan, AA; Muslim, S; Mustafa, G, 2015) |
| "They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease." | 1.40 | G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. ( Ferger, B; Hengerer, B; Oeckl, P, 2014) |
| " To test this hypothesis in a rodent model, the A2A receptor antagonists SCH 412348 (3 mg/kg), vipadenant (10 mg/kg), caffeine (30 mg/kg), or istradefylline (3 mg/kg) were chronically (19-22 days) administered to Sprague Dawley rats, and dyskinetic behaviors were scored across this chronic dosing paradigm." | 1.39 | A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. ( Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E, 2013) |
| "Catalepsy was measured using the bar test." | 1.39 | Somatostatin antagonist induces catalepsy in the aged rat. ( Ionov, ID; Pushinskaya, II, 2013) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| "Histamine was also found to damage the dopaminergic neurons in rat substantia nigra." | 1.38 | Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA. ( Ionov, ID; Severtsev, NN, 2012) |
| "In the catalepsy bar test, PPX-CR (1 mg/kg/day) reversed the haloperidol-induced motor impairment in the morning and over the whole observation period of 12h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Haloperidol treatment significantly induced the catalepsy as observed from increased descent time measured in the bar test." | 1.35 | Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. ( Alam, MM; Anwer, T; Azam, F; Barodia, SK, 2009) |
| "Treatment with caffeine significantly increased locomotion reduced by haloperidol, but not at all doses tested." | 1.35 | Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. ( Goode, T; Harris, A; Trevitt, J; Vallance, C, 2009) |
| "When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration." | 1.32 | Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent. ( Abercrombie, ED; Cobb, WS, 2003) |
| "Catalepsy, a symptom of Parkinson's disease and related disorders can be produced in rats and other laboratory animals by the blockade of nigrostriatal dopamine using dopaminergic antagonists such as haloperidol." | 1.31 | Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats. ( Field, EF; Pellis, SM; Whishaw, IQ, 2000) |
| "In addition to the diagnosis of chronic pseudoakathisia, five patients (62." | 1.31 | Prevalence and characteristics of patients with pseudoakathisia. ( Christodoulou, GN; Havaki-Kontaxaki, BJ; Kontaxakis, VP, 2000) |
| "Haloperidol was injected in doses of 0." | 1.29 | Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. ( Lorenc-Koci, E; Ossowska, K; Wolfarth, S, 1996) |
| "Further, when the HAL (1 mg/kg) catalepsy score was maximal (at 120 min), the rats were subjected to cold stress (3 degrees C for 10 min) or treated with NA, AD (2 micrograms/kg, i." | 1.29 | Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. ( Chopde, CT; Hote, MS; Mandhane, SN; Muthal, AV, 1995) |
| " It seemed sensible to investigate whether or not HP+ might be toxic towards dopaminergic neurons and perhaps associated with some of the residual moto-function side effects of haloperidol." | 1.29 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. ( Fang, J; Yu, PH; Zuo, D, 1995) |
| "Etiologic hypotheses for Parkinson's disease have implicated environmental factors, genetic factors, or a combination of the two." | 1.29 | Environmental exposures in elderly Canadians with Parkinson's disease. ( Chaturvedi, S; Hachinski, V; Merskey, H; Ostbye, T; Stoessl, AJ, 1995) |
| "The detection of VEP abnormalities in Parkinson's disease was dependent on the spatial frequency of the visual stimulus (a vertical square wave grating)." | 1.27 | Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. ( Basciani, M; Gambi, D; Ghilardi, MF; Onofrj, M, 1986) |
| "Pretreatment with reserpine and alpha-methyl-p-tyrosine did not alter the behavioral effects of ciladopa." | 1.27 | Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug. ( Fields, JZ; Gordon, JH; Koller, WC; Perlow, MJ, 1986) |
| " Two lines of evidence strongly suggest that the bursting pallidal activities are a consequence of the interruption of the nigrostriatal dopaminergic pathway: (1) the percentage of bursting pallidal neurons is proportional to the amount of degeneration in the pars compacta of the ipsilateral substantia nigra; (2) chronic administration of dopamine antagonists, haloperidol and reserpine, reproduces in intact monkeys the bursting activities observed in lesioned animals." | 1.26 | Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. ( Filion, M, 1979) |
| "Haloperidol was used in 12 patients in an attempt to improve l-dopa induced dyskinesias." | 1.25 | Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. ( Klawans, HL; Weiner, WJ, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 58 (41.73) | 18.7374 |
| 1990's | 20 (14.39) | 18.2507 |
| 2000's | 28 (20.14) | 29.6817 |
| 2010's | 22 (15.83) | 24.3611 |
| 2020's | 11 (7.91) | 2.80 |
| Authors | Studies |
|---|---|
| Bagli, J | 1 |
| Bogri, T | 1 |
| Voith, K | 1 |
| Azam, F | 2 |
| Alkskas, IA | 1 |
| Ahmed, MA | 1 |
| Banerjee, A | 1 |
| Patil, S | 1 |
| Pawar, MY | 1 |
| Gullapalli, S | 1 |
| Gupta, PK | 1 |
| Gandhi, MN | 1 |
| Bhateja, DK | 1 |
| Bajpai, M | 1 |
| Sangana, RR | 1 |
| Gudi, GS | 1 |
| Khairatkar-Joshi, N | 1 |
| Gharat, LA | 1 |
| Lindsley, CW | 4 |
| Hopkins, CR | 3 |
| Romero-Fernandez, W | 1 |
| Taura, JJ | 1 |
| Crans, RAJ | 1 |
| Lopez-Cano, M | 1 |
| Fores-Pons, R | 1 |
| Narváez, M | 1 |
| Carlsson, J | 1 |
| Ciruela, F | 1 |
| Fuxe, K | 1 |
| Borroto-Escuela, DO | 1 |
| Lawal, BA | 1 |
| Ayipo, YO | 1 |
| Adekunle, AO | 1 |
| Amali, MO | 1 |
| Badeggi, UM | 1 |
| Alananzeh, WA | 1 |
| Mordi, MN | 1 |
| Saleem, U | 4 |
| Khalid, S | 3 |
| Chauhdary, Z | 4 |
| Anwar, F | 3 |
| Shah, MA | 3 |
| Alsharif, I | 3 |
| Babalghith, AO | 3 |
| Khayat, RO | 3 |
| Albalawi, AE | 3 |
| Baokbah, TAS | 3 |
| Farrukh, M | 3 |
| Vargas-De-La-Cruz, C | 3 |
| Panichayupakaranant, P | 3 |
| Kotliarova, A | 2 |
| Podturkina, AV | 2 |
| Pavlova, AV | 3 |
| Gorina, DS | 2 |
| Lastovka, AV | 2 |
| Ardashov, OV | 3 |
| Rogachev, AD | 2 |
| Izyurov, AE | 2 |
| Arefieva, AB | 2 |
| Kulikov, AV | 2 |
| Tolstikova, TG | 3 |
| Volcho, KP | 3 |
| Salakhutdinov, NF | 3 |
| Sidorova, Y | 2 |
| Zhou, J | 1 |
| Li, J | 1 |
| Papaneri, AB | 1 |
| Cui, G | 1 |
| Rafiq, H | 1 |
| Farhan, M | 1 |
| Rafi, H | 1 |
| Rehman, S | 1 |
| Arshad, M | 1 |
| Shakeel, S | 1 |
| Kumar, S | 2 |
| Gupta, SK | 1 |
| Pahwa, R | 1 |
| Hussain, L | 1 |
| Masood, I | 1 |
| Ahmad, M | 1 |
| Ali, MY | 1 |
| Hussain, M | 1 |
| Khalid, SH | 1 |
| Łażewska, D | 1 |
| Olejarz-Maciej, A | 1 |
| Reiner, D | 1 |
| Kaleta, M | 1 |
| Latacz, G | 1 |
| Zygmunt, M | 1 |
| Doroz-Płonka, A | 1 |
| Karcz, T | 1 |
| Frank, A | 1 |
| Stark, H | 1 |
| Kieć-Kononowicz, K | 1 |
| Zaidi, AA | 1 |
| Khan, MA | 1 |
| Shahreyar, ZA | 1 |
| Ahmed, H | 1 |
| Kent, CN | 1 |
| Fulton, MG | 1 |
| Stillwell, KJ | 1 |
| Dickerson, JW | 2 |
| Loch, MT | 2 |
| Rodriguez, AL | 2 |
| Blobaum, AL | 3 |
| Boutaud, O | 1 |
| Rook, JL | 1 |
| Niswender, CM | 3 |
| Conn, PJ | 4 |
| Kumari, N | 1 |
| Agrawal, S | 1 |
| Luthra, PM | 1 |
| Dang, S | 1 |
| Nigam, K | 1 |
| Ali, J | 2 |
| Baboota, S | 2 |
| Barroca, NCB | 1 |
| Guarda, MD | 1 |
| da Silva, NT | 1 |
| Colombo, AC | 1 |
| Reimer, AE | 1 |
| Brandão, ML | 1 |
| de Oliveira, AR | 1 |
| Jones, N | 1 |
| Bleickardt, C | 1 |
| Mullins, D | 1 |
| Parker, E | 1 |
| Hodgson, R | 1 |
| Voronkov, DN | 1 |
| Khudoerkov, RM | 1 |
| Dovedova, EL | 1 |
| Oeckl, P | 1 |
| Hengerer, B | 1 |
| Ferger, B | 2 |
| Mustafa, G | 1 |
| Ahuja, A | 1 |
| Al Rohaimi, AH | 1 |
| Muslim, S | 1 |
| Hassan, AA | 1 |
| Anheim, M | 1 |
| Dowsey-Limousin, P | 1 |
| Krack, P | 1 |
| Chabardès, S | 1 |
| Benabid, AL | 1 |
| Pollak, P | 1 |
| Maurice, N | 1 |
| Deltheil, T | 1 |
| Melon, C | 2 |
| Degos, B | 1 |
| Mourre, C | 1 |
| Amalric, M | 3 |
| Kerkerian-Le Goff, L | 2 |
| Andrzejewski, K | 1 |
| Budzińska, K | 1 |
| Zaremba, M | 1 |
| Kaczyńska, K | 1 |
| Xue, Y | 1 |
| Yang, YT | 1 |
| Liu, HY | 1 |
| Chen, WF | 1 |
| Chen, AQ | 1 |
| Sheng, Q | 1 |
| Chen, XY | 1 |
| Wang, Y | 1 |
| Chen, H | 1 |
| Liu, HX | 1 |
| Pang, YY | 1 |
| Chen, L | 1 |
| Jones, CK | 2 |
| Lin, X | 1 |
| Bubser, M | 2 |
| Thompson Gray, A | 1 |
| Engers, DW | 2 |
| Daniels, JS | 2 |
| Javitch, JA | 1 |
| Moorjani, M | 3 |
| Luo, Z | 2 |
| Lin, E | 3 |
| Vong, BG | 1 |
| Chen, Y | 3 |
| Zhang, X | 3 |
| Rueter, JK | 2 |
| Gross, RS | 3 |
| Lanier, MC | 3 |
| Tellew, JE | 3 |
| Williams, JP | 3 |
| Lechner, SM | 3 |
| Malany, S | 3 |
| Santos, M | 3 |
| Crespo, MI | 3 |
| Díaz, JL | 3 |
| Saunders, J | 3 |
| Slee, DH | 3 |
| Barodia, SK | 1 |
| Anwer, T | 1 |
| Alam, MM | 1 |
| Markison, S | 2 |
| Joswig, T | 2 |
| Petroski, R | 1 |
| Piercey, J | 1 |
| Kargo, W | 1 |
| Wen, J | 1 |
| Jalali, K | 1 |
| O'Brien, Z | 1 |
| Stotz, CE | 1 |
| Neustadt, BR | 1 |
| Liu, H | 1 |
| Hao, J | 1 |
| Greenlee, WJ | 1 |
| Stamford, AW | 1 |
| Foster, C | 1 |
| Arik, L | 1 |
| Lachowicz, J | 1 |
| Zhang, H | 1 |
| Bertorelli, R | 1 |
| Fredduzzi, S | 1 |
| Varty, G | 1 |
| Cohen-Williams, M | 1 |
| Ng, K | 1 |
| Trevitt, J | 1 |
| Vallance, C | 1 |
| Harris, A | 1 |
| Goode, T | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Marti, M | 1 |
| Sarubbo, S | 1 |
| Latini, F | 1 |
| Cavallo, M | 1 |
| Eleopra, R | 1 |
| Biguzzi, S | 1 |
| Lettieri, C | 1 |
| Conti, C | 1 |
| Simonato, M | 1 |
| Zucchini, S | 1 |
| Quatrale, R | 1 |
| Sensi, M | 1 |
| Candeletti, S | 1 |
| Romualdi, P | 1 |
| Morari, M | 1 |
| Il'ina, IV | 1 |
| Morozova, EA | 1 |
| Korchagina, DV | 1 |
| Karpova, EV | 1 |
| Thompson, AD | 1 |
| Turle-Lorenzo, N | 1 |
| Bridges, TM | 1 |
| Morrison, RD | 1 |
| Jadhav, S | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Bennouar, KE | 1 |
| Uberti, MA | 1 |
| Bacolod, MD | 1 |
| Jimenez, HN | 1 |
| Cajina, M | 1 |
| Doller, D | 1 |
| Gubellini, P | 1 |
| Ionov, ID | 2 |
| Severtsev, NN | 1 |
| Gershteĭn, LM | 1 |
| Tatarintseva, IM | 1 |
| Sergutina, AV | 1 |
| Rakhmanova, VI | 1 |
| Pushinskaya, II | 1 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Lombardi, G | 1 |
| Varsaldi, F | 1 |
| Miglio, G | 1 |
| Papini, MG | 1 |
| Battaglia, A | 1 |
| Canonico, PL | 1 |
| Ossowska, K | 5 |
| Wardas, J | 3 |
| Pietraszek, M | 4 |
| Konieczny, J | 3 |
| Wolfarth, S | 5 |
| Cobb, WS | 1 |
| Abercrombie, ED | 1 |
| Darbaky, Y | 1 |
| Forni, C | 1 |
| Baunez, C | 1 |
| BORENSTEIN, P | 1 |
| DABBAH, M | 1 |
| BLES, G | 1 |
| Müller, JL | 1 |
| Deuticke, C | 1 |
| Putzhammer, A | 1 |
| Röder, CH | 1 |
| Hajak, G | 1 |
| Winkler, J | 1 |
| Johnston, TH | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 1 |
| Fox, SH | 1 |
| Brotchie, JM | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Honer, WG | 1 |
| Kopala, LC | 1 |
| Rabinowitz, J | 1 |
| Dekundy, A | 1 |
| Schaefer, D | 1 |
| Cenci, MA | 1 |
| Danysz, W | 1 |
| Kuter, K | 1 |
| Pilc, A | 1 |
| Chou, KL | 1 |
| Borek, LL | 1 |
| Friedman, JH | 1 |
| Preskorn, SH | 2 |
| Castro-Palomino, JC | 1 |
| Prat, M | 1 |
| Gual, S | 1 |
| Rajput, AH | 1 |
| Rozdilsky, B | 1 |
| Hornykiewicz, O | 2 |
| Shannak, K | 1 |
| Lee, T | 2 |
| Seeman, P | 3 |
| Wagner, HN | 1 |
| Zigmond, MJ | 1 |
| Stricker, EM | 1 |
| Meltzer, HY | 1 |
| Barbosa, ER | 1 |
| Marchiori, PE | 1 |
| Scaff, M | 1 |
| de Assis, JL | 1 |
| Herrera-Marschitz, M | 1 |
| Strömberg, I | 1 |
| Olsson, D | 1 |
| Ungerstedt, U | 1 |
| Olson, L | 1 |
| Diamond, BI | 1 |
| Pasinetti, G | 1 |
| Hitri, A | 1 |
| Borison, RL | 1 |
| Bédard, P | 2 |
| Boucher, R | 2 |
| Di Paolo, T | 1 |
| Labrie, F | 1 |
| Cheng, JT | 1 |
| Schallert, T | 1 |
| De Ryck, M | 1 |
| Teitelbaum, P | 1 |
| Titeler, M | 1 |
| Kinoshita, H | 1 |
| Hasegawa, T | 1 |
| Katsumata, Y | 1 |
| Kameyama, T | 1 |
| Yamamoto, I | 1 |
| Nabeshima, T | 1 |
| Lukhanina, EP | 1 |
| Kolomietz, BP | 1 |
| Prokopenko, VF | 1 |
| Rodionov, VA | 1 |
| Strange, PG | 1 |
| Kaneko, K | 1 |
| Yuasa, T | 1 |
| Miyatake, T | 1 |
| Tsuji, S | 1 |
| Fang, J | 1 |
| Zuo, D | 1 |
| Yu, PH | 1 |
| Lorenc-Koci, E | 2 |
| Chopde, CT | 2 |
| Hote, MS | 1 |
| Mandhane, SN | 2 |
| Muthal, AV | 1 |
| Erdmann, R | 1 |
| Krzaścik, P | 1 |
| Kostowski, W | 1 |
| Khisti, RT | 1 |
| Cardoso, F | 1 |
| Camargos, ST | 1 |
| Silva Júnior, GA | 1 |
| Bonfiglioli, C | 1 |
| De Berti, G | 1 |
| Nichelli, P | 1 |
| Nicoletti, R | 1 |
| Castiello, U | 1 |
| Stanzione, P | 2 |
| Bodis-Wollner, I | 1 |
| Pierantozzi, M | 1 |
| Semprini, R | 1 |
| Tagliati, M | 2 |
| Peppe, A | 1 |
| Bernardi, G | 1 |
| Field, EF | 1 |
| Whishaw, IQ | 1 |
| Pellis, SM | 1 |
| Bradley, SR | 1 |
| Marino, MJ | 1 |
| Wittmann, M | 1 |
| Rouse, ST | 1 |
| Awad, H | 1 |
| Levey, AI | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Kontaxakis, VP | 1 |
| Christodoulou, GN | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Michaluk, J | 1 |
| Romańska, I | 1 |
| Papla, I | 1 |
| Vetulani, J | 1 |
| Shad, MU | 1 |
| Marsh, C | 1 |
| Danielsen, EH | 1 |
| Smith, D | 1 |
| Hermansen, F | 1 |
| Gjedde, A | 1 |
| Cumming, P | 1 |
| Avissar, S | 1 |
| Roitman, G | 1 |
| Schreiber, G | 1 |
| Pérez de Francisco, C | 1 |
| Garnica Portillo, R | 1 |
| Filion, M | 1 |
| Calne, DB | 1 |
| Eisler, T | 1 |
| Marais, C | 1 |
| Martin, IC | 1 |
| Pöldinger, W | 1 |
| Bures, E | 1 |
| Haage, H | 1 |
| Ule, G | 1 |
| Struwe, O | 1 |
| Rajput, A | 1 |
| Farley, IJ | 1 |
| Beasley, BA | 1 |
| Ford, DH | 1 |
| Debono, AG | 1 |
| Marsden, CD | 1 |
| Parkes, JD | 1 |
| Kakimoto, Y | 1 |
| Ombrato, M | 1 |
| Capone, D | 1 |
| Stimmel, GL | 1 |
| Avakian, RM | 1 |
| Dutov, AA | 1 |
| Parkhomenko, VM | 1 |
| Corsini, GU | 1 |
| Zompo, MD | 1 |
| Cianchetti, C | 1 |
| Mangoni, A | 1 |
| Wesemann, W | 1 |
| Lawrence, MS | 1 |
| Redmond, DE | 1 |
| Gerlach, J | 1 |
| Casey, DE | 1 |
| Fattapposta, F | 1 |
| D'Alessio, C | 1 |
| Marciani, MG | 1 |
| Foti, A | 1 |
| Amabile, G | 1 |
| Carvey, PM | 1 |
| McRae, A | 1 |
| Ptak, LR | 1 |
| Kao, LC | 1 |
| Lo, ES | 1 |
| Goetz, CG | 1 |
| Tanner, CM | 1 |
| Penn, RD | 1 |
| Klawans, HL | 3 |
| Kellner, CH | 1 |
| Melvin, JA | 1 |
| Ryken, TC | 1 |
| Merrell, AN | 1 |
| Sonsalla, PK | 1 |
| Manzino, L | 1 |
| Heikkila, RE | 1 |
| Onofrj, M | 1 |
| Ghilardi, MF | 1 |
| Basciani, M | 1 |
| Gambi, D | 1 |
| Dietz, V | 1 |
| Berger, W | 1 |
| Horstmann, GA | 1 |
| Koller, W | 1 |
| Herbster, G | 1 |
| Anderson, D | 1 |
| Wack, R | 1 |
| Gordon, J | 1 |
| Giménez-Roldán, S | 1 |
| Mateo, D | 1 |
| Orbe, M | 1 |
| Muñoz-Blanco, JL | 1 |
| Hípola, D | 1 |
| Koller, WC | 1 |
| Fields, JZ | 1 |
| Gordon, JH | 1 |
| Perlow, MJ | 1 |
| Poirier, LJ | 2 |
| Langelier, P | 1 |
| Larochelle, L | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Chase, TN | 3 |
| Thulin, CA | 1 |
| Blom, S | 1 |
| Vogt, M | 1 |
| Arushanian, EB | 2 |
| Bruck, H | 1 |
| Gerstenbrand, F | 1 |
| Gnad, H | 1 |
| Gründig, E | 1 |
| Prosenz, P | 1 |
| Turunen, S | 1 |
| Achté, KA | 1 |
| Rosin, AJ | 1 |
| Itil, TM | 1 |
| Patterson, CD | 1 |
| Keskiner, A | 1 |
| Holden, JM | 1 |
| Weiner, WJ | 1 |
| Brindle, GF | 1 |
| Bruno, A | 1 |
| Bruno, SC | 1 |
| Nehlil, J | 1 |
| Brown, AS | 1 |
| Jenkins, R | 1 |
| Stoliarov, GV | 1 |
| Tolpyshev, BA | 1 |
| Barbeau, A | 1 |
| Marino, A | 1 |
| Ekdawi, MY | 1 |
| Fowke, R | 1 |
| Chaturvedi, S | 1 |
| Ostbye, T | 1 |
| Stoessl, AJ | 1 |
| Merskey, H | 1 |
| Hachinski, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease[NCT01341431] | Phase 2 | 50 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for haloperidol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Return of D
Topics: Animals; Drug Discovery; Humans; Ligands; Molecular Targeted Therapy; Neoplasms; Parkinson Disease; | 2017 |
An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats.
Topics: Animals; Benzoates; Catalepsy; Corpus Striatum; Enkephalins; Excitatory Amino Acid Antagonists; Glut | 2007 |
The management of psychosis in movement disorder patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Huntington Disease; Lewy Body Disease; Parkins | 2007 |
Dopamine autoreceptor stimulation: clinical significance.
Topics: Apomorphine; Dopamine; Haloperidol; Humans; Huntington Disease; Mental Disorders; Neurons; Parkinson | 1982 |
Radioreceptor labeling of pre- and postsynaptic dopamine receptors.
Topics: Animals; Apomorphine; Binding Sites; Haloperidol; Humans; Parkinson Disease; Radioligand Assay; Rece | 1980 |
Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Topics: Basal Ganglia; Basal Ganglia Diseases; Brain; Clozapine; Dopamine Agents; Dopamine D2 Receptor Antag | 1993 |
[Nicotine in neuropsychiatric movement disorders].
Topics: Adult; Akathisia, Drug-Induced; Brain; Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Nicotin | 1996 |
The pathogensis and medical treatment of extrapyramidal disease.
Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopami | 1979 |
[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Topics: Animals; Apomorphine; Benzamides; Chorea; Fluorescent Antibody Technique; Guinea Pigs; Haloperidol; | 1978 |
Aging and the extrapyramidal system.
Topics: Aged; Aging; Basal Ganglia Diseases; Chlorpromazine; Chorea; Dopamine; Frontal Lobe; Gait; Haloperid | 1976 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlor | 1974 |
Drug-induced changes in brain dopamine and their relation to parkinsonism.
Topics: Animals; Basal Ganglia; Brain; Cerebral Ventricles; Dihydroxyphenylalanine; Dopamine; Electric Stimu | 1970 |
[The role of dopamine in the physiology and pathology of the basal ganglia].
Topics: Basal Ganglia; Brain; Caudate Nucleus; Chlorpromazine; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1972 |
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
7 trials available for haloperidol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dopamine; Female; Fingers; Functional | 2003 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Kinematic analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects.
Topics: Adult; Age of Onset; Aged; Analysis of Variance; Antiparkinson Agents; Basal Ganglia; Chlorpromazine | 1998 |
Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Delayed-Action Preparat | 1975 |
Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.
Topics: Butyrophenones; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Haloperidol; | 1977 |
Comparison of phenothiazine and nonphenothiazine neuroleptics according to psychopathology, side effects and computerized EEG.
Topics: Alpha Rhythm; Chronic Disease; Clinical Trials as Topic; Computers; Electroencephalography; Female; | 1974 |
Effects of L-DOPA on pharmacological parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Haloper | 1966 |
118 other studies available for haloperidol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists.
Topics: Animals; Bromocriptine; Cycloheptanes; Disease Models, Animal; Hydroxydopamines; Male; Oxidopamine; | 1984 |
Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Brain; Catalepsy; Glutathione; Glutathione Pe | 2009 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relatio | 2012 |
The mGlu
Topics: Adenosine; Animals; Catalepsy; Dopamine; Haloperidol; HEK293 Cells; Humans; Mice; Parkinson Disease; | 2022 |
Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies.
Topics: alpha-Synuclein; Animals; Antioxidants; Antiparkinson Agents; Atropine Derivatives; Carbidopa; Choli | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic A | 2023 |
Inhibition of drug induced Parkinsonism by chronic supplementation of quercetin in haloperidol-treated wistars.
Topics: Animals; Antipsychotic Agents; Dietary Supplements; Haloperidol; Parkinson Disease; Quercetin; Rats | 2022 |
Designing lisuride intranasal nanocarrier system for reduction of oxidative damage with enhanced dopamine level in brain for Parkinsonism.
Topics: Animals; Antioxidants; Brain; Dopamine; Haloperidol; Lisuride; Oxidative Stress; Parkinson Disease; | 2023 |
Pharmacological and toxicological evaluation of methyl 4-hydroxy-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxoide against haloperidol induced Parkinson like symptoms in animal model: In-vitro and in-vivo studies.
Topics: Animals; Brain; Dopamine; Haloperidol; Mice; Parkinson Disease | 2023 |
Dual Target Ligands with 4-
Topics: Amines; Animals; Catalepsy; Cell Line, Tumor; Cell Proliferation; Haloperidol; HEK293 Cells; Histami | 2020 |
Lauric acid: Its role in behavioral modulation, neuro-inflammatory and oxidative stress markers in haloperidol induced Parkinson's disease.
Topics: Animals; Antioxidants; Biomarkers; Corpus Striatum; Cytokines; Haloperidol; Inflammation; Lauric Aci | 2020 |
Discovery and optimization of a novel CNS penetrant series of mGlu
Topics: Allosteric Regulation; Animals; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; | 2021 |
Pharmacological assessments of potent A
Topics: Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Antiparkinson Agents; | 2017 |
Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopamine Antag | 2018 |
Influence of aversive stimulation on haloperidol-induced catalepsy in rats.
Topics: Affect; Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopam | 2019 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia | 2013 |
[Changes in neuroglial interactions in the cerebral nigrostriatal structures in a model of dopamine system dysfunction].
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine Antagonists; Haloperidol; Neuroglia; Parkinson D | 2013 |
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cyclic AMP; Disease Models, Ani | 2014 |
Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.
Topics: Animals; Brain; Chemistry, Pharmaceutical; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopa | 2015 |
Subthalamic stimulation or subthalamic lesion for Parkinson's disease? A case report.
Topics: Adult; Antiparkinson Agents; Cabergoline; Chorea; Combined Modality Therapy; Deep Brain Stimulation; | 2015 |
Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.
Topics: Action Potentials; Animals; Basal Ganglia; Bee Venoms; Catalepsy; Disease Models, Animal; Dopamine A | 2015 |
Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Disease Mode | 2016 |
Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats.
Topics: Action Potentials; Animals; Benzoxazoles; Globus Pallidus; Haloperidol; Male; Naphthyridines; Neuron | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cata | 2016 |
2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability.
Topics: Adenosine A2 Receptor Antagonists; Aminopyridines; Chemistry, Pharmaceutical; Drug Design; Haloperid | 2008 |
Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; G | 2009 |
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Catalepsy; Disease Models, Animal; Drug Design; Drug Eva | 2008 |
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Catalepsy; Chemi | 2009 |
Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
Topics: Animals; Caffeine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Parkinson Disease | 2009 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.
Topics: Adrenergic Agents; Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic Agen | 2010 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Di | 2013 |
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Topics: Aging; Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Rel | 2012 |
[Morphochemical characteristics of hippocampal neuron's response to the hypofunction of the dopaminergic system].
Topics: Animals; Anti-Dyskinesia Agents; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Cell Nucleus; Cyt | 2012 |
Somatostatin antagonist induces catalepsy in the aged rat.
Topics: Age Factors; Aging; Animals; Brain; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Inject | 2013 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress.
Topics: Cabergoline; Cell Death; Cell Survival; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Recepto | 2002 |
The striopallidal pathway is involved in antiparkinsonian-like effects of the blockade of group I metabotropic glutamate receptors in rats.
Topics: Animals; Cataplexy; Corpus Striatum; Dopamine Antagonists; Enkephalins; Globus Pallidus; Haloperidol | 2003 |
Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
Topics: Animals; Dendrites; Dopamine; Dopamine Antagonists; Drug Synergism; Extracellular Space; GABA Antago | 2003 |
High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Catalepsy; Ch | 2003 |
[Apropos of the ultimate specificity of terrain in the appearance of extrapyramidal syndromes induced by neuroleptic agents].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Extrapyramidal Tracts; Haloperidol; Humans; Parkinson | 1962 |
The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Drug Administration Routes; | 2003 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Age | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2006 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; | 2008 |
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Catalepsy; C | 2008 |
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Male; Middle Aged; Parkinson Diseas | 1982 |
Imaging CNS receptors: the dopaminergic system.
Topics: Animals; Antipsychotic Agents; Apomorphine; Binding Sites; Brain; Carbon Radioisotopes; Deoxyglucose | 1984 |
Parkinson's disease: studies with an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology; | 1984 |
[Huntington chorea: report of 16 cases].
Topics: Adult; Aged; Brain Diseases; Chlorpromazine; Dementia; Diagnosis, Differential; Female; gamma-Aminob | 1983 |
Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics.
Topics: Adrenal Medulla; Animals; Disease Models, Animal; Flupenthixol; Haloperidol; Hydroxydopamines; Male; | 1984 |
Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain; Cholecystokinin; Dopamine; Drug Interactions; Extrapyramidal T | 1984 |
Interaction between estradiol, prolactin, and striatal dopaminergic mechanisms.
Topics: Animals; Corpus Striatum; Domperidone; Dopamine; Estradiol; Female; Haloperidol; Macaca fascicularis | 1984 |
Galloping induced by pontine tegmentum damage in rats: a form of "Parkinsonian festination" not blocked by haloperidol.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Locomotion; Male; Motor Activ | 1981 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol | 1994 |
Electrophysiological investigation of thalamic neuronal mechanisms of motor disorders in parkinsonism: an influence of D2ergic transmission blockade on excitation and inhibition of relay neurons in motor thalamic nuclei of cat.
Topics: Action Potentials; Afferent Pathways; Animals; Cats; Cerebellum; Dopamine; Dopamine D2 Receptor Anta | 1994 |
Stereotyped hand clasping: an unusual tardive movement disorder.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; | 1993 |
Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Line; Dose- | 1995 |
Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity.
Topics: Animals; Disease Models, Animal; Electromyography; Haloperidol; Joints; Male; Muscle Spasticity; Mus | 1996 |
Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.
Topics: Adrenalectomy; Animals; Catalepsy; Catecholamines; Glucocorticoids; Haloperidol; Male; Parkinson Dis | 1995 |
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide S | 1997 |
Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson's disease.
Topics: Animals; Antidepressive Agents; Catalepsy; Depressive Disorder; Drug Evaluation, Preclinical; Halope | 1997 |
Etiology of parkinsonism in a Brazilian movement disorders clinic.
Topics: Aged; Anti-Dyskinesia Agents; Brazil; Calcium Channel Blockers; Cinnarizine; Female; Flunarizine; Ha | 1998 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory | 1998 |
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations.
Topics: Adult; Brain; Electroencephalography; Electroretinography; Haloperidol; Humans; Parkinson Disease; R | 1999 |
Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats.
Topics: Animals; Biomechanical Phenomena; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Female; G | 2000 |
Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata.
Topics: Animals; Bridged Bicyclo Compounds; Catalepsy; Dopamine Antagonists; Excitatory Amino Acid Agonists; | 2000 |
Prevalence and characteristics of patients with pseudoakathisia.
Topics: Adult; Akathisia, Drug-Induced; Antiparkinson Agents; Antipsychotic Agents; Chlorpromazine; Chronic | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopami | 2000 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo | 2001 |
Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo.
Topics: Animals; Antipsychotic Agents; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Dopamine Antago | 2001 |
Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Brain Chemistry; Clozapine; Dopamine; Dopamine Ag | 2001 |
[Pharmacopsychiatry and iatrogenic parkinsonism].
Topics: Antiparkinson Agents; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Parkinson Disease; Parki | 1978 |
Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey.
Topics: Animals; Apomorphine; Corpus Striatum; Evoked Potentials; Globus Pallidus; Haloperidol; Haplorhini; | 1979 |
[Cerebral degenerative change in association with dyskinesia following neuroleptic treatment (author's transl)].
Topics: Female; Haloperidol; Humans; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, | 1978 |
Receptor basis for dopaminergic supersensitivity in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Caudate Nucleus; Dopamine; Haloperidol; Homovanillic Acid; Humans; Levodop | 1978 |
alpha and beta Dopamine receptors?
Topics: Apomorphine; Chorea; Haloperidol; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Torticol | 1976 |
[Biochemical studies of schizophrenia].
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Brain; Dopamine; Haloperidol; Humans; Parkinson Disease; S | 1976 |
[Treatment of Parkinson's disease associated with psychosis].
Topics: Aged; Female; Haloperidol; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 1975 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
[Preconvulsive state and hyperfunction of the striatum (clinico-experimental findings)].
Topics: Adolescent; Adult; Aged; Animals; Apomorphine; Convulsants; Corpus Striatum; Electroencephalography; | 1976 |
Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism.
Topics: Adult; Apomorphine; Drug Therapy, Combination; Haloperidol; Humans; Male; Metoclopramide; Parkinson | 1976 |
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 1992 |
MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys.
Topics: Animals; Apomorphine; Blinking; Chlorocebus aethiops; Dopamine Agents; Haloperidol; Male; MPTP Poiso | 1991 |
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Topics: Animals; Antipsychotic Agents; Arousal; Benzamides; Cebus; Disease Models, Animal; Dyskinesia, Drug- | 1990 |
Dopaminergic pharmacological manipulations in normal humans confirm the specificity of the visual (PERG-VEP) and cognitive (P300) electrophysiological alterations in Parkinson's disease.
Topics: Acoustic Stimulation; Cognition; Dopamine; Electroencephalography; Evoked Potentials, Auditory; Evok | 1990 |
Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor.
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Animals; Autoantibodies; Cells, Cultured; Cerebellum; Corp | 1990 |
Neuroleptic malignant syndrome associated with basal ganglia hemorrhage.
Topics: Aged; Basal Ganglia; Basal Ganglia Diseases; Cerebral Hemorrhage; Dementia; Haloperidol; Humans; Mal | 1989 |
Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism.
Topics: Aged; Female; Haloperidol; Humans; Lorazepam; Neuroleptic Malignant Syndrome; Parkinson Disease | 1989 |
Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Basal Ganglia; Benzazepines; Co | 1988 |
Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.
Topics: Adult; Aged; Brain; Carbidopa; Dopamine; Evoked Potentials, Visual; Female; Haloperidol; Humans; Lev | 1986 |
Posture in Parkinson's disease: impairment of reflexes and programming.
Topics: Adult; Aged; Dopamine Antagonists; Electromyography; Gait; Haloperidol; Humans; Leg; Middle Aged; Mu | 1988 |
Quinpirole hydrochloride, a potential anti-parkinsonism drug.
Topics: Animals; Benzazepines; Corpus Striatum; Dogs; Dose-Response Relationship, Drug; Ergolines; Grooming; | 1987 |
Acute pharmacologic tests in cranial dystonia.
Topics: Adult; Aged; Basal Ganglia Diseases; Clonazepam; Diagnosis, Differential; Double-Blind Method; Femal | 1988 |
Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Body Temperature; Dogs; Dose-Response Relationship, Drug | 1986 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Fronta | 1974 |
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Topics: Adult; Basal Ganglia Diseases; Brain; Central Nervous System Diseases; Dopamine; Haloperidol; Homova | 1973 |
Rigidity and tremor induced in feline muscles deprived of their fusiomtor control.
Topics: Achilles Tendon; Animals; Animals, Newborn; Cats; Disease Models, Animal; Electromyography; Haloperi | 1974 |
[Comparative biochemical studies in organic parkinsonian syndromes and drug induced parkinsonian syndromes].
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biochemical Phenomena; Biochemistry; Chlorpromazi | 1966 |
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
Topics: Adult; Aged; Brain Damage, Chronic; Cheek; Chlorpromazine; Chlorprothixene; Clopenthixol; Female; Ha | 1967 |
Proceedings: Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dioxoles; Dopamine; Haloperidol; Homovanillic Acid; Hu | 1974 |
Clinical features, etiology and treatment of facial dyskinesias in the elderly.
Topics: Age Factors; Aged; Brain; Brain Damage, Chronic; Brain Stem; Chorea; Dementia; Dopamine; Face; Femal | 1974 |
Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dioxoles; Dopamine; Drug Evaluation; Haloperidol; Homovanillic Acid; Humans; L | 1974 |
Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.
Topics: Adult; Aged; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; M | 1974 |
The use of neuroleptic agents in a neurosurgical unit.
Topics: Benperidol; Cerebral Angiography; Chlorpromazine; Craniocerebral Trauma; Electrodes; Epilepsy; Fenta | 1969 |
[Persisting extrapyramidal syndrome following neuroleptic therapy].
Topics: Amines; Brain; Dopamine; Extrapyramidal Tracts; Haloperidol; Humans; Parkinson Disease; Parkinson Di | 1969 |
Neuroleptanalgesia.
Topics: Alcoholism; Analgesics; Bronchography; Burns; Dextromoramide; Fentanyl; Haloperidol; Hearing Disorde | 1969 |
Laevo-dopa for Parkinsonism.
Topics: Dihydroxyphenylalanine; Haloperidol; Humans; Parkinson Disease; Trifluoperazine | 1970 |
[The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Topics: Amphetamine; Caudate Nucleus; Female; Haloperidol; Humans; Male; Parkinson Disease; Parkinson Diseas | 1970 |
Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
Topics: Administration, Oral; Animals; Dihydroxyphenylalanine; Haloperidol; Humans; Movement Disorders; Musc | 1970 |
[Parkinsonian and neurodysleptic syndromes during treatment with neuroleptic drugs].
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease; Psychotic Diso | 1965 |
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Haloperidol; Humans; Middle Aged; Orphenadrine; Parasympatholytic | 1966 |
Environmental exposures in elderly Canadians with Parkinson's disease.
Topics: Adhesives; Aged; Canada; Data Collection; Environmental Exposure; Epoxy Resins; Female; Humans; Male | 1995 |